Astrocytes Discovery Sends Alzheimer's Research in a New Direction

by Staff Writer
April 17, 2023 at 11:05 AM UTC

The α-synuclein seed amplification assay shows promise in early Parkinson's disease diagnosis and could lead to personalized treatment.

Clinical Relevance: Scientists have begun exploring theories about the cause of Alzheimer’s other than a build up of protein plaques in the brain

  • When astrocytes (a type of glial support cell) take up too much acetate they change into dangerous reactive astrocytes associated with Alzheimer’s.
  • Using this information, South Korean scientists developed imaging that was able to capture neuronal metabolism  changes in mouse models and patients with Alzheimer’s.
  • Reactive astrocytes also created an imbalance of an inhibitory neurotransmitter called GABA, a phenomenon also linked to the development of Alzheimer’s dementia.

Alzheimer’s disease has long been attributed to a buildup of plaque in the brain. As scientists begin to explore alternative theories, new research on astrocytes is getting some attention. 

Reactive Astrocytes

Astrocytes are a type of glial cell in the brain and spinal cord that provide structural and metabolic support to neurons. The cells perform a variety of functions, including regulating the chemical environment, promoting synapse formation, and repairing damaged brain tissue. 

South Korean scientists recently demonstrated that when astrocytes take up elevated levels of acetates–a type of molecule produced as a byproduct of metabolism–they transform into dangerous reactive astrocytes. Reactive astrocytes have emerged as a suspected culprit in the development and progression of Alzheimer’s disease.

New Imaging Technique

The scientists used their insights to develop a new imaging technique to directly observe the astrocyte-neuron interactions. Using positron emission tomography (PET) imaging with radioactive acetate and glucose probes (11C-acetate and 18F-FDG) they were able to visualize the changes in neuronal metabolism in patients with Alzheimer’s. 

Amyloid Load and Depression in Older Adults

OCD and Dementia Risk

Treatment Challenges in Early-Stage AD (Free CME)

Imaging also spotted a strong correlation between cognitive function and the PET signals of both 11C-acetate and 18F-FDG. It found high levels of acetate and low levels of glucose in both mouse and human brains. And, it was able to directly attribute those changes to reactive astrocytes in the brain.

“Reactive astrocytes showed metabolic abnormalities that excessively uptake acetate compared to normal state. We found that the acetate plays an important role in promoting astrocytic inflammatory responses,” YUN Mijin, one of the paper’s authors, commented.

In the mouse model, the researchers took it one step further by reversing the metabolic changes. This inhibited reactive astrogliosis and astrocytic MCT1 expression which, in turn, halted the formation of the harmful reactive astrocytes and prevented them from taking up too much acetate. 

Comparison of C-acetate and 18F-FDG PET imaging in an adenovirus model with different treatments and genetic modifications.
Comparison of C-acetate and 18F-FDG PET imaging in an adenovirus model with different treatments and genetic modifications. (Credit | IBS)

GABA Involvement

When astrocytes uptake too much acetate this also boosted the production of another molecule called GABA (gamma-aminobutyric acid), the researchers found. GABA is an inhibitory neurotransmitter that reduces the activity of neurons. By preventing overstimulation, the molecule helps regulate a variety of brain functions, including anxiety, sleep, and muscle control. 

Previous studies suggest that an imbalance of GABA is bad for the brain. When levels are too high in certain regions, it can lead to neurological disorders like Alzheimer’s. A similar mechanism has also been implicated in epilepsy, depression, and schizophrenia.

Shifting Theories

More than six million Americans are affected by Alzheimer’s, according to the Alzheimer’s Association. The prevailing hypothesis on this neurodegenerative disease has long been that amyloid beta plaques cause neuroinflammation in the brain. However, targeting these plaques has shown little success in treating or slowing its progression.

The new research provides some early evidence that acetate and the MCT1 transporter could be a new target in Alzheimer’s. The researchers believe that 11C-acetate and 18F-FDG PET imaging might be a tool for early diagnosis of Alzheimer’s dementia. With further development, they added, it could also lead to breakthrough treatments.

A. C-acetate and 18F-FDG PET imaging can visualize reactive astrogliosis and neuronal glucose hypometabolism in AD patients' brains. B. Multiple correlations between 11C-acetate SUVR, 18F-FDG SUVR in the entorhinal cortex and hippocampus, and MMSE scores. (Credit | IBS)
A. C-acetate and 18F-FDG PET imaging can visualize reactive astrogliosis and neuronal glucose hypometabolism in AD patients’ brains. B. Multiple correlations between 11C-acetate SUVR, 18F-FDG SUVR in the entorhinal cortex and hippocampus, and MMSE scores. (Credit | IBS)

__________________________________________________________

The research was funded by the Institute for Basic Science (IBS.) IBS has 4 research institutes and 33 research centers as of January 2023.

A Randomized, Double-Blind, Placebo-Controlled Pilot Trial of the Acute Antisuicidal and Antidepressant Effects of Intranasal (R,S)-Ketamine in Severe Unipolar and Bipolar Depression With and Without Comorbid Alcohol Use Disorder

Intranasal ketamine induced rapid antidepressant effects versus placebo but did not significantly change suicidal ideation scores in patients with alcohol use disorder and suicidal ideation with past attempt.

Gregory H. Jones and others

Case Report

Inhalant Screening in Early Adolescence: Missed Opportunity to Prevent Escalation to Polysubstance Use and Related Consequences

The authors present a case of polysubstance use in an adolescent for whom undetected inhalant use played a key role in escalation of substance use and psychiatric comorbidities.

Jennifer Yokoyama and others